^Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T, Nakatani Y, Ohsawa F, Nishikawa N, Sugai M, Suzuki M, Aoki K, Kitaguchi H (May 2006). "Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor". The Journal of Pharmacology and Experimental Therapeutics. 317 (2): 562–70. doi:10.1124/jpet.105.099705. PMID16436501. S2CID6064389.
^Walker MW, Wolinsky TD, Jubian V, Chandrasena G, Zhong H, Huang X, Miller S, Hegde LG, Marsteller DA, Marzabadi MR, Papp M, Overstreet DH, Gerald CP, Craig DA (Mar 2009). "The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity". The Journal of Pharmacology and Experimental Therapeutics. 328 (3): 900–11. doi:10.1124/jpet.108.144634. PMID19098165. S2CID20295744.
^Islam I, Dhanoa D, Finn J, Du P, Walker MW, Salon JA, Zhang J, Gluchowski C (Jul 2002). "Discovery of potent and selective small molecule NPY Y5 receptor antagonists". Bioorganic & Medicinal Chemistry Letters. 12 (13): 1767–9. doi:10.1016/S0960-894X(02)00287-1. PMID12067557.
Further reading
Parker E, Van Heek M, Stamford A (Apr 2002). "Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status". European Journal of Pharmacology. 440 (2–3): 173–87. doi:10.1016/S0014-2999(02)01427-9. PMID12007534.
Berglund MM, Schober DA, Statnick MA, McDonald PH, Gehlert DR (Jul 2003). "The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor agonist-induced beta-arrestin 2 interaction". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 147–56. doi:10.1124/jpet.103.051227. PMID12665544. S2CID40163065.